MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Results 1 - 20 of 174 : 1 2 3 4 5 6 7 8 9 Next »

Recs

0
Member Avatar PrototypeZ (23.50) Submitted: 1/5/2016 4:53:29 PM : Underperform Start Price: $0.66 MNKD Score: -39.47

Sanofi's Afrezza exit from the partnership does not bode well for MannKind

Recs

0
Member Avatar coleman205 (< 20) Submitted: 1/5/2016 11:04:16 AM : Underperform Start Price: $1.05 MNKD Score: +9.00

Sanofi

Recs

0
Member Avatar CheeseNMac (78.36) Submitted: 12/2/2015 10:05:08 PM : Underperform Start Price: $3.04 MNKD Score: +68.67

If things haven't come together for MNKD yet, I doubt they will at all. I also wonder if SNY entered this partnership merely to box MNKD out and and purchase the company on the cheap when it fails.

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 11/17/2015 4:34:23 PM : Underperform Start Price: $2.24 MNKD Score: +51.65

The last time I green thumbed Mannkind I felt like the company would pull yet another rabbit out of the hat to confound the shorts and bring at least temporary joy to the hearts of longs. Sadly, it now appears unequivocal that the Afrezza launch has failed and Sanofi will likely terminate the partnership in 2016. Mannkind has resorted to desperate measures to refill their diminishing cash reserves such as the recent dual-listing in Tel Aviv. I miscalculated this one time but I think this red thumb will enshrine my score leadership in stone as the company swirls towards bankruptcy.

Recs

1
Member Avatar NajdorfSicilian (99.89) Submitted: 10/28/2015 5:17:53 PM : Underperform Start Price: $3.65 MNKD Score: +65.07

still overvalued

Recs

0
Member Avatar FineArtist (< 20) Submitted: 9/4/2015 9:22:32 AM : Underperform Start Price: $3.72 MNKD Score: +72.67

A game changer for type 2 diabetes patients.

Recs

0
Member Avatar drugtrader (90.45) Submitted: 8/12/2015 12:12:52 PM : Outperform Start Price: $4.21 MNKD Score: -67.86

Decent product (small, simple to use) with a niche use (meal time, precision glucose control)

Surprised they beat q2, bought 1k shares that I can hopefully refrain from trading as I feel 2016 could be a good year

Recs

0
Member Avatar Herbstmd (35.54) Submitted: 7/25/2015 11:41:23 AM : Underperform Start Price: $5.03 MNKD Score: +72.24

Poor product with limited use, inhalable insulin will be replaced by a cheaper tablet soon.

Recs

0
Member Avatar Turtlebale (62.65) Submitted: 7/21/2015 4:16:27 PM : Underperform Start Price: $5.31 MNKD Score: +71.46

Afrezza

Recs

0
Member Avatar Isaacroo (< 20) Submitted: 4/29/2015 1:10:47 PM : Outperform Start Price: $4.65 MNKD Score: -69.50

Afrezza is going to create tons of $$ revenue diabetes is at an all time high, they will hit 10$ again, and it's hopefully bottomed out

Recs

0
Member Avatar TMFTypeoh (71.52) Submitted: 4/27/2015 2:46:44 PM : Outperform Start Price: $4.57 MNKD Score: -68.74

Stock is been brutal for longs, but Afrezza looks promising. The action curve is so fast, it could be a game changer. Or, it could be a total failure. I'm willing to give a thumbs up to the longs at these prices. Multi bagger or a dud.

Recs

1
Member Avatar jmccolley (< 20) Submitted: 2/6/2015 4:07:45 PM : Outperform Start Price: $7.00 MNKD Score: -78.07

Afrezza will be the first inhaled insulin to actually become accepted by patients, doctors and insurance companies.
It is easy to use and the inhaler fits in the palm of your hand.
It is smaller than the inhalers used by asthma patients.
The technosphere device is revolutionary and will change the way many medications are delivered.

Recs

1
Member Avatar nugjuice (< 20) Submitted: 2/3/2015 4:28:43 PM : Outperform Start Price: $6.50 MNKD Score: -77.49

The bear case just doesn't resonate, and a lot of people have written Afrezza off without knowing much about the product. It's been unfairly (but understandably) compared to Exubera, which differs not only in its bulkiness, but also in its efficacy. Exubera was less effective than injected insulin (and much more expensive) which meant the only value-added was being able to inhale instead of inject. Afrezza not only is inhaled (with an inhaler the size of a whistle instead of a bong) but it also has better efficacy and a faster acting profile than traditional injected meds, with competitive pricing. With 30% of the float short, this is a no-brainer with reward positively skewed to the upside

Recs

1
Member Avatar FoundryOnStocks (20.50) Submitted: 1/27/2015 3:21:35 PM : Outperform Start Price: $6.33 MNKD Score: -77.53

$9 price target by February 2016.

Recs

0
Member Avatar missjessiecat (< 20) Submitted: 1/13/2015 12:59:34 PM : Outperform Start Price: $5.61 MNKD Score: -75.37

Although there is still substantial risk in MNKD, I believe the risk will dwindle considerably over the next 12 months and I also believe that the upside potential is enormous! If I'm right about these two predictions, as the risk goes down, the share price will explode. Afrezza sales should be very strong this year and many more opportunities will develop that makes use of their Technosphere technolgy! I just can't believe that the current share price is this low!

Recs

0
Member Avatar JCLscapXperiment (99.34) Submitted: 12/14/2014 6:57:28 PM : Underperform Start Price: $5.14 MNKD Score: +74.81

Jan17 Put $1, $3 Strike

Recs

0
Member Avatar rbitrage (96.40) Submitted: 10/13/2014 9:26:29 PM : Underperform Start Price: $4.71 MNKD Score: +79.87

Not much cash on the books. The company has financial problems and the current market won't allow the company to go back to the market to get more equity.

Recs

0
Member Avatar SegaRob (24.19) Submitted: 10/2/2014 4:03:58 PM : Outperform Start Price: $5.55 MNKD Score: -79.02

There is a huge market for Afrezza (inhaled insulin) and the technosphere technology that allows medications that previously required injections to be taken via an inhaler. Revenues from Afrezza are likely to be north of $1b in 2015 and further growth after that especially since there continues to be a rise in diabetic patients. Stock is currently trading at market cap close to $2b. I think the stock is worth at least $10 making current price of $5.55 a big bargain.

Recs

0
Member Avatar beppaun (67.85) Submitted: 10/2/2014 3:49:14 PM : Outperform Start Price: $5.56 MNKD Score: -79.58

One of the highest short interest ratio for a company that could be near profitability after agreement with Sanofi

Recs

0
Member Avatar jbwheels69 (55.24) Submitted: 10/1/2014 1:32:26 PM : Outperform Start Price: $5.55 MNKD Score: -79.49

Great partner in SNY leader in the diabetes space. Great potential to be a block buster.

Featured Broker Partners